



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
-----------------	-------------	----------------------	---------------------	------------------

10/517,214

03/01/2005

Tsuyoshi Maekawa

10525.0004

7396

22852

7590

04/03/2008

FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER
LLP

901 NEW YORK AVENUE, NW
WASHINGTON, DC 20001-4413

EXAMINER

JAISLE, CECILIA M

ART UNIT

PAPER NUMBER

1624

MAIL DATE

DELIVERY MODE

04/03/2008

PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary	Application No. 10/517,214	Applicant(s) MAEKAWA ET AL.	
	Examiner CECILIA M. JAISLE	Art Unit 1624	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 13 September 2007.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-33 is/are pending in the application.
- 4a) Of the above claim(s) 32 and 33 is/are withdrawn from consideration.
- 5) ☒ Claim(s) 31 is/are allowed.
- 6) ☒ Claim(s) 1-16 and 18-30 is/are rejected.
- 7) ☒ Claim(s) 17 is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☒ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☒ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☒ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|--|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413) |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | Paper No(s)/Mail Date. _____ |
| 3) <input checked="" type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08) | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| Paper No(s)/Mail Date <u>03-04-2005 & 11-23-2004</u> . | 6) <input type="checkbox"/> Other: _____ |

DETAILED OFFICE ACTION

Lack of Unity

Applicants' election of Group I, claims 1-31 with traverse in the Response of Sep. 13, 2007 is acknowledged. Claims 1-31 are under examination only to the extent that they recite the subject matter of Group I, substituted pyrazole compounds of Formula I, pharmaceutical compositions thereof and therapeutic methods therewith. Otherwise, claims 1-31 are withdrawn from examination. Claims 32 and 33 are withdrawn from examination as directed to the subject matter of non-elected Groups IV and V.

Applicants traverse on the ground that there would not be an undue burden in examining all the subject matter of all the claims in a single application, pointing to the electronic search tools available to examiners. In addition to the search burden, each group as set forth in the Lack of Unity in the Office Action of Aug. 17, 2007 lacks unity with each other group, i.e., there is no single general inventive concept. The unique special technical features in each group are the identities of the nitrogen containing 1,2-azole ring of Formula I and the other nitrogen containing 1,2-azole rings of other Formulae of the disclosure. The technical relationship among the inventions does not involve at least one common or corresponding special technical feature. The expression "special technical feature" is defined as meaning those technical features that define the contribution which each claimed invention, considered as a whole, makes over the prior art. In this case, a reference that could be used to reject

substituted Pyrazole compounds of Formula I of Group I could not be used to reject substituted Isoxazole compounds of Formula I of Group II.

The Group I invention has special technical features not common to Group II and would be expected to be useful other than as disclosed, e.g., as PPAR ligand receptor binders (WO 06/064888). Also, the Group II invention has special technical features not common to Group I and would be expected to be useful other than as disclosed, e.g., as crop protection agents (CA Pat. 2100546).

Accordingly, the Lack of Unity is indeed proper and is made Final.

Rejections Under 35 USC 112

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claims 1, 8, 12, 14, 15, 18 and 20-30 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claim 1: Xb and Yb, or Xc and Yc cannot both possibly simultaneously be a bond without any intervening atoms. When Xa, Xb, Xc, Yb and Yc are each a bond, the character of the bond is not identified, i.e., covalent, ionic, single, double, triple, van der Waals' bonds, etc. The terms "hydroxy-protecting group" and "amino-protecting group" are undefined. The recitation of "salt" fails to point out and distinctly claim the intended subject matter, especially when the asserted utility of the claimed compounds is as pharmaceuticals, so that the salts should be pharmaceutically acceptable.

Claims 8 and 20-30: The terms “hydroxy-protecting group” and “amino-protecting group” have been commented on in regard to claim 1.

Claims 12, 14 and 15: The term “bond” was commented on in regard to claim 1.

Claim 18 is indistinct and confusing, because it is not possible to determine if the claimed salt is formed of the compound or of the prodrug of the compound or of both.

Claims 20-30: The intended use recited for the pharmaceutical compositions is given no patentable weight and renders these claims substantial duplicates of each other to the extent that they recite the same chemical compounds.

Claims 20, 28 and 29: The term “diabetes” fails to point out and distinctly claim the intended subject matter, since it encompasses Type-I diabetes, Type-II diabetes, diabetes insipidus, gestational diabetes, neurogenic diabetes, nephrogenic diabetes and dipsogenic diabetes. Each of these diseases requires different treatment. As far as is known, no treatment is a prophylaxis against development of diabetes.

Claim 22: The treatment of arteriosclerosis focuses on relief of symptoms and improvement of circulation. Applicants fail to identify what symptoms the claimed compounds alleviate. Prevention of arteriosclerosis consists in controlling obesity and high blood pressure and avoiding smoking, but Applicants fail to disclose how the claimed compositions assist in such inhibitory factors. As far as is known, only the above-mentioned life-style changes are a prophylaxis against arteriosclerosis.

Rejections Under 35 USC 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(a) the invention was known or used by others in this country, or patented or described in a printed publication in this or a foreign country, before the invention thereof by the applicant for a patent.

Claims 1-6, 8, 9, 11, 13, 15 and 16 are rejected under 35 U.S.C. 102(a) as being anticipated by Environmental Protection Agency, Federal Register (~~2002~~), 67(188), 60886-60902, 27 Sep 2002, describing RN 512165-96-7, Carbamic acid, [2-[[[1-(4-chlorophenyl)-1H-pyrazol-3-yl]oxy]methyl]phenyl]-, methyl ester, useful as a pesticide.

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claims 1-6, 8, 9, 11, 15 and 16 are rejected under 35 U.S.C. 102(b) as being anticipated by Kajino, et al., WO 2002023986, published 20020328, describing

- RN 405545-51-9, Benzeneacetic acid, 2-[[acetyl(3,5-dimethyl-1-phenyl-1H-pyrazol-4-yl)amino]methyl]- α -(methoxymethylene)-, methyl ester;
- RN 405545-53-1, Benzoic acid, 3-[[acetyl(3,5-dimethyl-1-phenyl-1H-pyrazol-4-yl)amino]methyl]-;
- RN 405545-54-2, Benzoic acid, 3-[[acetyl(3,5-dimethyl-1-phenyl-1H-pyrazol-4-yl)amino]methyl]-, methyl ester;
- RN 405545-55-3, Benzoic acid, 3-[[acetyl(3,5-dimethyl-1-phenyl-1H-pyrazol-4-yl)amino]methyl]-, ethyl ester;

Art Unit: 1624

- RN 405545-56-4, Benzoic acid, 3-[[acetyl(3,5-dimethyl-1-phenyl-1H-pyrazol-4-yl)amino]methyl]-, 1-methylethyl ester;
- RN 405545-57-5, Benzamide, 3-[[acetyl(3,5-dimethyl-1-phenyl-1H-pyrazol-4-yl)amino]methyl]-;
- RN 405545-58-6, Benzamide, 3-[[acetyl(3,5-dimethyl-1-phenyl-1H-pyrazol-4-yl)amino]methyl]-N-methyl-;
- RN 405545-59-7, Benzamide, 3-[[acetyl(3,5-dimethyl-1-phenyl-1H-pyrazol-4-yl)amino]methyl]-N-propyl-;
- RN 405545-60-0, Benzamide, 3-[[acetyl(3,5-dimethyl-1-phenyl-1H-pyrazol-4-yl)amino]methyl]-N-(cyanomethyl)-;
- RN 405545-68-8, Benzamide, 3-[[acetyl(3,5-dimethyl-1-phenyl-1H-pyrazol-4-yl)amino]methyl]-N-(1-oxopropyl)-; and
- RN 405546-72-7, Benzoic acid, 3-[[[(3,5-dimethyl-1-phenyl-1H-pyrazol-4-yl)(1-thioxoethyl)amino]methyl]-, ethyl ester;

useful as agrochemicals, i.e., for control of *Phytophthora infestans*.

Claims 1-6, 8, 9, 13, 15 and 19-30 are rejected under 35 U.S.C. 102(b) over Fahmy, et al., Archives of Pharmacal Research (2001), 24(3), 180-189, describing RN 442129-55-7, Benzamide, 2-[2-(5-amino-3-phenyl-1H-pyrazol-1-yl)-2-oxoethoxy]-; useful for anti-inflammatory, analgesic, antipyretic and ulcerogenic activities. Note that the intended use of the pharmaceutical compositions is given no patentable weight.

Claims 1-6, 9, 11, 12, 14 and 15 are rejected under 35 U.S.C. 102(b) over Donohue, et al., Journal of Combinatorial Chemistry (2002), 4(1), 23-32, describing RN 385412-59-9, Benzoic acid, 4-[[[1-(4-ethyl-2-thiazolyl)-5-(trifluoromethyl)-1H-pyrazol-4-yl]carbonyl]amino]methyl]-, methyl ester; and RN 385412-60-2, Benzoic acid, 4-[[[1-[4-(1,1-dimethylethyl)-2-thiazolyl]-5-(trifluoromethyl)-1H-pyrazol-4-yl]carbonyl]amino]methyl]-, methyl ester, have nematocidal activity, e.g. toxic to *C. elegans*.

Claims 1-6, 9, 11-13 and 15 are rejected under 35 U.S.C. 102(b) as being anticipated by Wachendorff-Neumann, et al., DE 10019758, published 20011025, describing RN 175013-18-0, Carbamic acid, N-[2-[[[1-(4-chlorophenyl)-1H-pyrazol-3-yl]oxy]methyl]phenyl]-N-methoxy-, methyl ester, useful as fungicides.

Claims 1-7, 9, 11, 12, 14, 15 and 18-30 are rejected under 35 U.S.C. 102(b) as being anticipated by Gerhaeuser, et al., WO 2001074753, published 20011011, describing

- RN 365542-56-9, Benzoic acid, 2-[(1E)-2-(5-chloro-3-methyl-1-phenyl-1H-pyrazol-4-yl)ethenyl]-6-methoxy-, methyl ester;
- RN 365542-57-0, Benzoic acid, 2-[2-(5-chloro-3-methyl-1-phenyl-1H-pyrazol-4-yl)ethyl]-6-methoxy-, methyl ester, monohydrochloride;
- RN 365542-58-1, Benzoic acid, 2-[(1E)-2-(5-chloro-3-methyl-1-phenyl-1H-pyrazol-4-yl)ethenyl]-6-methoxy-, ethyl ester;

Art Unit: 1624

- RN 365542-59-2, Benzoic acid, 2-[2-(5-chloro-3-methyl-1-phenyl-1H-pyrazol-4-yl)ethenyl]-6-methoxy-, methyl ester;
- RN 365542-60-5, Benzoic acid, 2-[(1Z)-2-(5-chloro-3-methyl-1-phenyl-1H-pyrazol-4-yl)ethenyl]-6-methoxy-, methyl ester, monohydrochloride;
- RN 365542-61-6, Benzoic acid, 2-[2-(5-chloro-3-methyl-1-phenyl-1H-pyrazol-4-yl)ethenyl]-6-methoxy-, methyl ester, monohydrochloride; and
- RN 365542-74-1, Benzoic acid, 2-[2-(5-chloro-3-phenyl-4-isoxazolyl)ethenyl]-6-methoxy-, methyl ester;

useful as chemopreventive agents. The intended use of the pharmaceutical compositions is given no patentable weight.

Claims 1-7, 9, 11 and 14-16 are rejected under 35 U.S.C. 102(b) as being anticipated by Heinemann, et al., DE 19961330, published 20010621; describing

- RN 344569-93-3, Benzeneacetic acid, 2-[[[1-(4-chlorophenyl)-1H-pyrazol-3-yl]oxy]methyl]- α -[(fluoromethoxy)methylene]-, methyl ester;
- RN 344569-94-4, Benzeneacetic acid, 2-[[[1-[4-(1,1-dimethylethyl)phenyl]-1H-pyrazol-3-yl]oxy]methyl]- α -[(fluoromethoxy)methylene]-, methyl ester;
- RN 344569-95-5, Benzeneacetic acid, α -[(fluoromethoxy)methylene]-2-[[[1-(4-fluorophenyl)-1H-pyrazol-3-yl]oxy]methyl]-, methyl ester;
- RN 344569-96-6, Benzeneacetic acid, α -[(fluoromethoxy)methylene]-2-[[[1-[4-(1-methylethyl)phenyl]-1H-pyrazol-3-yl]oxy]methyl]-, methyl ester;

Art Unit: 1624

- RN 344569-97-7, Benzeneacetic acid, 2-[[[1-(3-bromophenyl)-1H-pyrazol-3-yl]oxy]methyl]- α -[(fluoromethoxy)methylene]-, methyl ester;
- RN 344569-98-8, Benzeneacetic acid, 2-[[[1-(4-bromophenyl)-1H-pyrazol-3-yl]oxy]methyl]- α -[(fluoromethoxy)methylene]-, methyl ester;
- RN 344569-99-9, Benzeneacetic acid, 2-[[[1-(3,5-dichlorophenyl)-1H-pyrazol-3-yl]oxy]methyl]- α -[(fluoromethoxy)methylene]-, methyl ester;
- RN 344570-00-9, Benzeneacetic acid, 2-[[[1-(2-chlorophenyl)-1H-pyrazol-3-yl]oxy]methyl]- α -[(fluoromethoxy)methylene]-, methyl ester;
- RN 344570-01-0, Benzeneacetic acid, 2-[[[1-(4-cyanophenyl)-1H-pyrazol-3-yl]oxy]methyl]- α -[(fluoromethoxy)methylene]-, methyl ester;
- RN 344570-02-1, Benzeneacetic acid, α -[(fluoromethoxy)methylene]-2-[[[1-(4-methylphenyl)-1H-pyrazol-3-yl]oxy]methyl]-, methyl ester;
- RN 344570-03-2, Benzeneacetic acid, 2-[[[1-(2,4-dichlorophenyl)-1H-pyrazol-3-yl]oxy]methyl]- α -[(fluoromethoxy)methylene]-, methyl ester;
- RN 344570-04-3, Benzeneacetic acid, 2-[[[1-(2-bromophenyl)-1H-pyrazol-3-yl]oxy]methyl]- α -[(fluoromethoxy)methylene]-, methyl ester;
- RN 344570-05-4, Benzeneacetic acid, α -[(fluoromethoxy)methylene]-2-[[[1-(phenyl)-1H-pyrazol-3-yl]oxy]methyl]-, methyl ester;
- RN 344570-06-5, Benzeneacetic acid, 2-[[[1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-1H-pyrazol-3-yl]oxy]methyl]- α -[(fluoromethoxy)methylene]-, methyl ester;

Useful as fungicides, insecticides and acaricides.

Claims 1-9, 11, 12, 14, 15 and 18 are rejected under 35 U.S.C. 102(b) as being anticipated by Selwood, et al., WO 2001032604, published 20010510, describing RN 338980-58-8, Benzamide, 2-[[[(5-chloro-1-methyl-3-phenyl-1H-pyrazol-4-yl)methyl]thio]-N-[3-(dimethylamino)propyl]-; and RN 338980-88-4, Urea, N-[2-[[[(5-chloro-1-methyl-3-phenyl-1H-pyrazol-4-yl)methyl]thio]phenyl]-N'-[3-(dimethylamino)propyl]-; useful as activators of soluble guanylate cyclase.

Claims 1-7, 9, 11, 14-16 and 19-30 are rejected under 35 U.S.C. 102(b) as being anticipated by Shinoda, et al., WO 2001025181, published 20010412, describing

- RN 334012-76-9, Benzenepropanoic acid, 4-methoxy- α -(1-methylethoxy)-3-[[[(1-methyl-3-phenyl-1H-pyrazol-5-yl)carbonyl]amino]methyl]-;
- RN 334012-77-0, Benzenepropanoic acid, 4-methoxy- α -(1-methylethoxy)-3-[[[(1-methyl-5-phenyl-1H-pyrazol-3-yl)carbonyl]amino]methyl]-;
- RN 334012-79-2, Benzenepropanoic acid, 4-methoxy- α -(1-methylethoxy)-3-[[[(1-methyl-5-(2-pyridinyl)-1H-pyrazol-3-yl)carbonyl]amino]methyl]-;
- RN 334012-80-5, Benzenepropanoic acid, 4-methoxy- α -(1-methylethoxy)-3-[[[(1-methyl-3-(2-pyridinyl)-1H-pyrazol-5-yl)carbonyl]amino]methyl]-;
- RN 334012-86-1, Benzenepropanoic acid, 4-methoxy- α -(1-methylethoxy)-3-[[[(3-methyl-1-phenyl-1H-pyrazol-5-yl)carbonyl]amino]methyl]-; and
- RN 334012-87-2, Benzenepropanoic acid, 4-methoxy- α -(1-methylethoxy)-3-[[[(5-methyl-1-phenyl-1H-pyrazol-3-yl)carbonyl]amino]methyl]-;

Art Unit: 1624

Useful in insulin resistance improvement. The intended use of the pharmaceutical compositions is given no patentable weight.

Claims 1-7, 9, 11, 12, 14, 15, 18 and 19-30 are rejected under 35 U.S.C. 102(b) as being anticipated by Hargreaves, et al., WO 2001012612, published 20010222; describing

- RN 326912-92-9, Benzoic acid, 2-[[3-(3-bromo-4-methylphenyl)-1H-pyrazol-1-yl]methyl]-, ethyl ester;
- RN 326912-93-0, Benzoic acid, 2-[[3-[3-bromo-4-(bromomethyl)phenyl]-1H-pyrazol-1-yl]methyl]-, ethyl ester;
- RN 326912-94-1, Benzoic acid, 2-[[3-[3-bromo-4-[(methylamino)methyl]phenyl]-1H-pyrazol-1-yl]methyl]-, ethyl ester;
- RN 326912-98-5, Benzoic acid, 2-[[3-(3-chloro-4-methylphenyl)-1H-pyrazol-1-yl]methyl]-, methyl ester; and
- RN 326912-99-6, Benzoic acid, 2-[[3-[4-(bromomethyl)-3-chlorophenyl]-1H-pyrazol-1-yl]methyl]-, methyl ester;

Useful for treatment of diabetes mellitus. The intended use of the pharmaceutical compositions is given no patentable weight.

Claims 1-9 and 11-15 are rejected under 35 U.S.C. 102(b) as being anticipated by Emeric, et al., WO 2001002385, published 20010111; describing RN 318492-52-3, 1,3-Benzenedicarboxylic acid, 5-[[1-(7-chloro-4-quinolinyl)-4-(methoxycarbonyl)-1H-

Art Unit: 1624

pyrazol-5-yl]methoxy]-, dimethyl ester; and RN 318492-66-9, 1,3-Benzenedicarboxylic acid, 5-[[4-(methoxycarbonyl)-1-[8-(trifluoromethyl)-4-quinolinyl]-1H-pyrazol-5-yl]methoxy]-, dimethyl ester; useful as fungicides.

Claims 1-9 and 11-15 are rejected under 35 U.S.C. 102(b) as being anticipated by Schelberger, et al., WO 2000030450, published 20000602, describing RN 216659-76-6, Carbamic acid, [2-[[[1-(4-chlorophenyl)-1H-pyrazol-3-yl]oxy]-methyl]phenyl]-methoxy-, methyl ester, mixture with copper hydroxide sulfate; and RN 271249-36-6, Carbamic acid, methoxy[2-[[[1-(4-methylphenyl)-1H-pyrazol-3-yl]oxy]methyl]phenyl]-, methyl ester, mixture with copper hydroxide sulfate; useful as fungicides.

Claims 1-9 and 11-15 are rejected under 35 U.S.C. 102(b) as being anticipated by Walter, et al., WO 2000027200, published 20000518, describing RN 175013-33-9, Carbamic acid, [2-[[[1-(4-fluorophenyl)-1H-pyrazol-3-yl]oxy]methyl]phenyl]methoxy-, methyl ester, useful as a fungicide.

Claims 1-9, 11, 15 and 19-30 are rejected under 35 U.S.C. 102(b) over Kikuchi, et al., Bioorganic & Medicinal Chemistry Letters (*2000*), 10(7), 619-622, describing RN 270585-16-5, Benzoic acid, 4-[4-[1-(2,5-dimethylphenyl)-5-(1-methylethyl)-1H-pyrazol-3-yl]-1,4-dioxobutyl]-, methyl ester, useful as a retinoic acid receptor α agonist. The intended use of the pharmaceutical compositions has no patentable weight.

Art Unit: 1624

Claims 1-9, 11, 12, 14 and 15 are rejected under 35 U.S.C. 102(b) as being anticipated by Hasegawa, et al., JP 2000053649 A, published 20000222, describing

- RN 257954-72-6, Benzoic acid, 4-[[[(5-amino-4-cyano-1-phenyl-1H-pyrazol-3-yl)acetyl]amino]-, ethyl ester;
- RN 257954-77-1, Benzoic acid, 3-[[[(5-amino-4-cyano-1-phenyl-1H-pyrazol-3-yl)acetyl]amino]-, ethyl ester; and
- RN 257954-82-8, Benzoic acid, 2-[[[(5-amino-4-cyano-1-phenyl-1H-pyrazol-3-yl)acetyl]amino]-, ethyl ester;

Useful as intermediates to sulfonylureidopyrazoles as endothelin converting enzyme inhibitors.

Claims 1-7, 9, 11 and 14-16 are rejected under 35 U.S.C. 102(b) as being anticipated by Desbordes, et al., FR 2773155 A1, published 19990702, describing

- RN 252280-47-0, Benzeneacetic acid, α -(methoxymethylene)-2-[[[(1-methyl-5-phenyl-1H-pyrazol-3-yl)oxy]methyl]-, methyl ester, (α E)-;
- RN 252280-48-1, Benzeneacetic acid, α -(methoxyimino)-2-[[[(5-phenyl-1H-pyrazol-3-yl)oxy]methyl]-, methyl ester, (α E)-;
- RN 252280-49-2, Benzeneacetamide, α -(methoxyimino)-N-methyl-2-[[[(5-phenyl-1H-pyrazol-3-yl)oxy]methyl]-, (α E)-;
- RN 252280-50-5, Benzeneacetic acid, α -ethylidene-2-[[[(5-phenyl-1H-pyrazol-3-yl)oxy]methyl]-, methyl ester, (α E)-;

Art Unit: 1624

- RN 252280-51-6, Carbamic acid, methoxy[2-[(5-phenyl-1H-pyrazol-3-yl)oxy]methyl]phenyl]-, methyl ester; and
- RN 252280-52-7, Benzeneacetic acid, α -methoxy-2-[(5-phenyl-1H-pyrazol-3-yl)oxy]methyl]-, methyl ester;

Useful as fungicides

Claims 1-9 and 11-13 are rejected under 35 U.S.C. 102(b) as being anticipated by Sato, et al., JP 11263775 A, 19990928, describing

- RN 244175-52-8, Carbamic acid, [2-methyl-4-[(5-methyl-1-phenyl-1H-pyrazol-3-yl)methoxy]phenyl]-, methyl ester;
- RN 244175-57-3, Carbamic acid, [2-methyl-4-[(3-methyl-1-phenyl-1H-pyrazol-5-yl)methoxy]phenyl]-, methyl ester;
- RN 244175-58-4, Carbamic acid, [2-methyl-4-[[1-phenyl-3-(trifluoromethyl)-1H-pyrazol-5-yl]methoxy]phenyl]-, methyl ester;
- RN 244175-59-5, Carbamic acid, [2-methyl-4-[[3-(pentafluoroethyl)-1-phenyl-1H-pyrazol-5-yl]methoxy]phenyl]-, methyl ester; and
- RN 244175-61-9, Carbamic acid, [4-[[1-(4-chlorophenyl)-5-(trifluoromethyl)-1H-pyrazol-4-yl]methoxy]-2-methylphenyl]-, methyl ester;

useful as herbicides.

Claims 1-9, 11-15 and 19-30 are rejected under 35 U.S.C. 102(b) as being anticipated by Kitaide, et al., JP 11130753 A, published 19990518, describing

Art Unit: 1624

- RN 225930-55-2, Benzoic acid, 4-[[1-(4-chlorophenyl)-5-methyl-1H-pyrazol-4-yl]methoxy]-, methyl ester;
- RN 225930-56-3, Benzoic acid, 4-[[[1-(4-chlorophenyl)-5-methyl-1H-pyrazol-4-yl]methyl]methylamino]-, ethyl ester;
- RN 225930-59-6, Benzoic acid, 4-[[5-methyl-1-(4-pyridinyl)-1H-pyrazol-4-yl]methoxy]-, methyl ester;
- RN 225930-67-6, Benzoic acid, 4-[[1-(4-chlorophenyl)-5-methyl-1H-pyrazol-4-yl]methoxy]-;
- RN 225930-68-7, Benzoic acid, 4-[(5-methyl-1-phenyl-1H-pyrazol-4-yl)methoxy]-, methyl ester;
- RN 225930-69-8, Benzoic acid, 4-[[1-(4-chlorophenyl)-1H-pyrazol-4-yl]methoxy]-, methyl ester;
- RN 225930-70-1, Benzoic acid, 4-[[1-(4-chlorophenyl)-5-methyl-1H-pyrazol-4-yl]methoxy]-, ethyl ester;
- RN 225930-72-3, Benzoic acid, 4-[[5-methyl-1-(2-pyridinyl)-1H-pyrazol-4-yl]methoxy]-, methyl ester;
- RN 225930-73-4, Benzoic acid, 4-[[1-(4-methoxyphenyl)-5-methyl-1H-pyrazol-4-yl]methoxy]-, methyl ester;
- RN 225930-74-5, Benzoic acid, 4-[[3-(dimethylamino)-1-phenyl-1H-pyrazol-4-yl]methoxy]-, methyl ester;
- RN 225930-75-6, Benzoic acid, 4-[[1-(4-chlorophenyl)-5-(dimethylamino)-1H-pyrazol-4-yl]methoxy]-, methyl ester;

Art Unit: 1624

- RN 225930-76-7, Benzoic acid, 4-[[1-(4-chlorophenyl)-5-methyl-1H-pyrazol-4-yl]methoxy]-3-methoxy-, methyl ester;
- RN 225930-77-8, Benzoic acid, 3-chloro-4-[[1-(4-chlorophenyl)-5-methyl-1H-pyrazol-4-yl]methoxy]-, ethyl ester;
- RN 225930-78-9, Benzoic acid, 3-chloro-4-[(5-methyl-1-phenyl-1H-pyrazol-4-yl)methoxy]-, ethyl ester;
- RN 225930-80-3, Benzoic acid, 4-[[1-(4-chlorophenyl)-1H-pyrazol-4-yl]methoxy]-;
- RN 225930-81-4, Benzoic acid, 4-[[1-[4-(dimethylamino)phenyl]-5-methyl-1H-pyrazol-4-yl]methoxy]-, ethyl ester;
- RN 225930-82-5, Benzoic acid, 4-[[1-methyl-5-(1H-pyrrol-1-yl)-1H-pyrazol-4-yl]methoxy]-, methyl ester;
- RN 225930-83-6, Benzoic acid, 4-[[5-methyl-1-(4-methylphenyl)-1H-pyrazol-4-yl]methoxy]-, ethyl ester;
- RN 225930-84-7, Benzoic acid, 4-[[1-(4-fluorophenyl)-5-methyl-1H-pyrazol-4-yl]methoxy]-, ethyl ester;
- RN 225930-86-9, Benzoic acid, 4-[[5-methyl-1-(2-pyridinyl)-1H-pyrazol-4-yl]methoxy]-;
- RN 225930-87-0, Benzoic acid, 4-[[1-(4-methoxyphenyl)-5-methyl-1H-pyrazol-4-yl]methoxy]-;
- RN 225930-88-1; Benzoic acid, 4-[[5-methyl-1-(4-pyridinyl)-1H-pyrazol-4-yl]methoxy]-;

Art Unit: 1624

- RN 225930-90-5, Benzoic acid, 4-[[1-(4-chlorophenyl)-5-methyl-1H-pyrazol-4-yl]methoxy]-3-methoxy-;
- RN 225930-91-6, Benzoic acid, 3-chloro-4-[[1-(4-chlorophenyl)-5-methyl-1H-pyrazol-4-yl]methoxy]-;
- RN 225930-92-7, Benzoic acid, 3-chloro-4-[(5-methyl-1-phenyl-1H-pyrazol-4-yl)methoxy]-;
- RN 225930-94-9, Benzoic acid, 4-[[[1-(4-chlorophenyl)-5-methyl-1H-pyrazol-4-yl]methyl]methylamino]-; and
- RN 225930-95-0, Benzoic acid, 4-[[[1-(4-chlorophenyl)-5-methyl-1H-pyrazol-4-yl]methoxy]methyl]-;

Useful as lipid formation inhibitors. The intended use of the pharmaceutical compositions is given no patentable weight.

Claims 1-9 and 11-15 are rejected under 35 U.S.C. 102(b) as being anticipated by Klintz, et al., US 6255489, issued 20010703, describing

- RN 220897-48-3, Carbamic acid, hydroxy[2-[(1-phenyl-1H-pyrazol-3-yl)oxy]methyl]phenyl]-, methyl ester;
- RN 220897-58-5, Urea, N-hydroxy-N'-methyl-N-[2-[(1-phenyl-1H-pyrazol-3-yl)oxy]methyl]phenyl]-;
- RN 220897-76-7, Carbamic acid, [2-[[[1-(4-chlorophenyl)-1H-pyrazol-3-yl]oxy]methyl]phenyl]hydroxy-, methyl ester;

Art Unit: 1624

- RN 220897-80-3, Urea, N-[2-[[[1-(4-chlorophenyl)-1H-pyrazol-3-yl]oxy]methyl]phenyl]-N-hydroxy-N'-methyl-;
- RN 220897-86-9, Carbamic acid, [2-[[[1-(4-chlorophenyl)-5-methyl-1H-pyrazol-3-yl]oxy]methyl]phenyl]methoxy-, methyl ester;
- RN 220897-91-6, Carbamic acid, [2-[[[1-cyclohexyl-4-(trifluoromethyl)-1H-pyrazol-3-yl]oxy]methyl]phenyl]methoxy-, methyl ester;
- RN 220897-96-1, Carbamic acid, [2-[[[4-chloro-1-(5-chloro-2-pyridinyl)-1H-pyrazol-3-yl]oxy]methyl]phenyl]methoxy-, methyl ester;
- RN 220898-10-2, Urea, N-methoxy-N'-methyl-N-[2-[[[1-phenyl-1H-pyrazol-3-yl]oxy]methyl]phenyl]-;
- RN 220898-33-9, Urea, N-[2-[[[1-(2,4-dichlorophenyl)-1H-pyrazol-3-yl]oxy]methyl]phenyl]-N-methoxy-N'-methyl-;

Useful as intermediates for crop protection agents.

Claims 1-9, 12, 14 and 15 are rejected under 35 U.S.C. 102(b) as being anticipated by Wu, et al., US 5965491, issued 19991012, describing RN 217437-17-7, Benzamide, 3-[[1-[5-amino-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-4- (methylsulfinyl)-1H-pyrazol-3-yl]ethylidene]amino]-, useful as pesticides.

Claims 1-7, 9, 11, 12 and 14-16 are rejected under 35 U.S.C. 102(b) as being anticipated by Grote, et al., US 5985919, issued 19991116, describing RN 184883-56-

Art Unit: 1624

5, 2-Butenoic acid, 2-[3-[2-[4-chloro-3-(4-chlorophenyl)-5-isoxazolyl]ethenyl]phenoxy]-, methyl ester, useful as insecticides and fungicides.

Claims 1-7, 9, 11, 12 and 14-16 are rejected under 35 U.S.C. 102(b) as being anticipated by Mueller, et al., US 5935986, issued 19990810, describing

- RN 184684-07-9, Benzeneacetic acid, 2-[[[1-(4-chlorophenyl)-1H-pyrazol-3-yl]oxy]methyl]- α -(methoxymethylene)-, methyl ester;
- RN 184684-08-0, Benzeneacetic acid, α -(methoxymethylene)-2-[[[1-(4-methylphenyl)-1H-pyrazol-3-yl]oxy]methyl]-, methyl ester;
- RN 184684-09-1, Benzeneacetic acid, 2-chloro-6-[[[1-(4-chlorophenyl)-1H-pyrazol-3-yl]oxy]methyl]- α -(methoxymethylene)-, methyl ester;
- RN 184684-10-4, Benzeneacetic acid, 2-chloro-6-[[[1-(2,4-dichlorophenyl)-1H-pyrazol-3-yl]oxy]methyl]- α -(methoxymethylene)-, methyl ester;
- RN 184684-11-5, Benzeneacetic acid, α -(methoxymethylene)-2-[[[1-[5-(trifluoromethyl)-2-pyridinyl]-1H-pyrazol-3-yl]oxy]methyl]-, methyl ester;
- RN 184684-12-6, Benzeneacetic acid, α -(methoxymethylene)-2-[[[1-[4-(trifluoromethoxy)phenyl]-1H-pyrazol-3-yl]oxy]methyl]-, methyl ester;
- RN 184684-13-7, Benzeneacetic acid, α -(methoxymethylene)-2-[[[1-pyrazinyl-1H-pyrazol-3-yl]oxy]methyl]-, methyl ester;
- RN 184684-15-9, Benzeneacetic acid, 2-[[[1-(6-chloro-2-pyridinyl)-1H-pyrazol-3-yl]oxy]methyl]- α -(methoxymethylene)-, methyl ester;

Art Unit: 1624

- RN 184684-22-8, Benzeneacetic acid, 2-[[[1-(4-chlorophenyl)-1H-pyrazol-4-yl]oxy]methyl]- α -(methoxymethylene)-, methyl ester;
- RN 184684-23-9, Benzeneacetic acid, 2-[[[1-(2-chloro-4-fluorophenyl)-1H-pyrazol-3-yl]oxy]methyl]- α -(methoxymethylene)-, methyl ester;
- RN 184684-24-0, Benzeneacetic acid, 2-[[[1-(2,4-dichlorophenyl)-1H-pyrazol-3-yl]oxy]methyl]- α -(methoxymethylene)-, methyl ester;
- RN 184684-25-1, Benzeneacetic acid, 2-[[[1-(5-chloro-2-pyridinyl)-1H-pyrazol-3-yl]oxy]methyl]- α -(methoxymethylene)-, methyl ester;
- RN 184684-26-2, Benzeneacetic acid, 2-[[[1-(2,4-difluorophenyl)-1H-pyrazol-3-yl]oxy]methyl]- α -(methoxymethylene)-, methyl ester; and
- RN 184684-27-3, Benzeneacetic acid, α -(methoxymethylene)-2-[[[1-phenyl-1H-pyrazol-4-yl]oxy]methyl]-, methyl ester;

Useful as fungicides.

Claims 1-7, 9, 11, 14 and 15 are rejected under 35 U.S.C. 102(b) over Kolehmainen, et al., Journal of the Chemical Society, Perkin Transactions 2: Physical Organic Chemistry (1996), (11), 2383-2387, describing RN 186140-69-2, Benzoic acid, 4-[[[3-methyl-1-phenyl-1H-pyrazol-5-yl]imino]methyl]-, methyl ester.

Claims 1-11, 13-15 and 19-30 are rejected under 35 U.S.C. 102(b) as being anticipated by Ohara, et al., WO 9611196, published 19960418, describing RN 179099-26-4, 1H-Pyrazole-3-carboxylic acid, 1-methyl-5-[2-(5-methyl-1-phenyl-1H-pyrazol-4-yl)-

Art Unit: 1624

2-oxoethoxy]-, ethyl ester; useful as hypoglycemic agents and aldose-reductase inhibitors. The intended use of the compositions is given no patentable weight.

Claims 1-7, 9, 11 and 13-15 are rejected under 35 U.S.C. 102(b) as being anticipated by Oberdorf, et al., WO 9607633, published 19960314, describing

- RN 178428-10-9, Benzeneacetic acid, α -methoxy-2-[[[1-phenyl-1H-pyrazol-3-yl]oxy]methyl]-, methyl ester;
- RN 178428-11-0, Benzeneacetic acid, α -methoxy-2-[[[1-(4-methylphenyl)-1H-pyrazol-3-yl]oxy]methyl]-, methyl ester;
- RN 178428-12-1, Benzeneacetic acid, 2-[[[1-(4-chlorophenyl)-1H-pyrazol-3-yl]oxy]methyl]- α -methoxy-, methyl ester;
- RN 178428-13-2, Benzeneacetic acid, 2-[[[1-(2,4-dichlorophenyl)-1H-pyrazol-3-yl]oxy]methyl]- α -methoxy-, methyl ester;
- RN 178428-19-8, Benzeneacetic acid, α -methoxy-2-[[[1-[5-(trifluoromethyl)-2-pyridinyl]-1H-pyrazol-3-yl]oxy]methyl]-, methyl ester;
- RN 178428-20-1, Benzeneacetic acid, 2-[[[4-chloro-1-[5-(trifluoromethyl)-2-pyridinyl]-1H-pyrazol-3-yl]oxy]methyl]- α -methoxy-, methyl ester;
- RN 178428-65-4, Benzeneacetamide, 2-[[[1-(2,4-dichlorophenyl)-1H-pyrazol-3-yl]oxy]methyl]- α -methoxy-N-methyl-;
- RN 178428-66-5, Benzeneacetamide, 2-[[[1-(4-chlorophenyl)-1H-pyrazol-3-yl]oxy]methyl]- α -methoxy-N-methyl-;

- RN 178428-71-2, Benzeneacetamide, α -methoxy-N-methyl-2-[[[1-phenyl-1H-pyrazol-3-yl]oxy]methyl]-;
- RN 178428-72-3, Benzeneacetamide, α -methoxy-N-methyl-2-[[[1-(4-methylphenyl)-1H-pyrazol-3-yl]oxy]methyl]-;
- RN 178428-87-0, Benzeneacetic acid, 2-[[[1-(4-chlorophenyl)-1H-pyrazol-3-yl]oxy]methyl]- α -ethoxy-, methyl ester;
- RN 178428-94-9, Benzeneacetic acid, 2-[[[1-(4-fluorophenyl)-1H-pyrazol-3-yl]oxy]methyl]- α -methoxy-, methyl ester;
- RN 178428-95-0, Benzeneacetamide, 2-[[[1-(4-fluorophenyl)-1H-pyrazol-3-yl]oxy]methyl]- α -methoxy-N-methyl-; and
- RN 178428-96-1, Benzeneacetamide, 2-[[[1-(4-chlorophenyl)-1H-pyrazol-3-yl]oxy]methyl]- α -ethoxy-N-methyl-;

Useful as fungicides.

Claims 1, 4-7, 10-12, 14 and 15 are rejected under 35 U.S.C. 102(b) as being anticipated by Marzin, et al., *Inorganica Chimica Acta* (~~1996~~), 246(1-2), 217-227, describing RN 180518-76-7, 1H-Pyrazole-3-carboxylic acid, 5-methoxy-1-[[5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl]methyl]-, ethyl ester.

Claims 1-7, 9, 12 and 14- 16 are rejected under 35 U.S.C. 102(b) as being anticipated by Kirstgen, et al., US 5506254, issued 19960409, describing

Art Unit: 1624

- RN 175424-53-0, Benzeneacetamide, 2-[2-[1-(2,4-dichlorophenyl)-5-(trifluoromethyl)-1H-pyrazol-4-yl]ethenyl]- α -(methoxyimino)-N-methyl-, (E,E)-;
- RN 175424-54-1, Benzeneacetamide, 2-[2-[1-(3-chlorophenyl)-5-(trifluoromethyl)-1H-pyrazol-4-yl]ethenyl]- α -(methoxyimino)-N-methyl-, (E,E)-;
- RN 175424-55-2, Benzeneacetamide, α -(methoxyimino)-N-methyl-2-[2-[1-(4-methylphenyl)-5-(trifluoromethyl)-1H-pyrazol-4-yl]ethenyl]-, (E,E)-;
- RN 175424-56-3, Benzeneacetamide, 2-[2-[1-(4-chlorophenyl)-5-(trifluoromethyl)-1H-pyrazol-4-yl]ethenyl]- α -(methoxyimino)-N-methyl-, (E,E)-;
- RN 175424-57-4, Benzeneacetamide, 2-[2-[1-(2,4-dichlorophenyl)-1H-pyrazol-4-yl]ethenyl]- α -(methoxyimino)-N-methyl-, (E,E)-;
- RN 175424-58-5, Benzeneacetamide, 2-[2-[1-(4-chlorophenyl)-1H-pyrazol-4-yl]ethenyl]- α -(methoxyimino)-N-methyl-, (E,E)-;
- RN 175424-60-9, Benzeneacetamide, 2-[2-[1-(2,4-dichlorophenyl)-5-methyl-1H-pyrazol-4-yl]ethenyl]- α -(methoxyimino)-N-methyl-, (E,E)-;
- RN 175424-61-0, Benzeneacetamide, 2-[2-[5-chloro-1-(2,4-dichlorophenyl)-1H-pyrazol-4-yl]ethenyl]- α -(methoxyimino)-N-methyl-, (E,E)-;
- RN 175424-62-1, Benzeneacetamide, 2-[2-[5-chloro-1-(4-chlorophenyl)-1H-pyrazol-4-yl]ethenyl]- α -(methoxyimino)-N-methyl-, (E,E)-;
- RN 175424-63-2, Benzeneacetamide, 2-[2-[5-chloro-1-(3-chlorophenyl)-1H-pyrazol-4-yl]ethenyl]- α -(methoxyimino)-N-methyl-, (E,E)-;

Art Unit: 1624

- RN 175424-64-3, Benzeneacetamide, α -(methoxyimino)-N-methyl-2-[2-(1-phenyl-1H-pyrazol-4-yl)ethenyl]-, (E,E)-;
- RN 175424-65-4, Benzeneacetamide, 2-[2-[1-(2-chlorophenyl)-5-(trifluoromethyl)-1H-pyrazol-4-yl]ethenyl]- α -(methoxyimino)-N-methyl-, (E,E)-;
- RN 175424-66-5, Benzeneacetamide, 2-[2-[1-(4-fluorophenyl)-5-(trifluoromethyl)-1H-pyrazol-4-yl]ethenyl]- α -(methoxyimino)-N-methyl-, (E,E)-;
- RN 175424-67-6, Benzeneacetamide, 2-[2-[1-(3,5-dichlorophenyl)-5-(trifluoromethyl)-1H-pyrazol-4-yl]ethenyl]- α -(methoxyimino)-N-methyl-, (E,E)-;
- RN 175424-68-7, Benzeneacetamide, α -(methoxyimino)-2-[2-[1-(4-methoxyphenyl)-5-(trifluoromethyl)-1H-pyrazol-4-yl]ethenyl]-N-methyl-, (E,E)-;
- RN 175424-69-8, Benzeneacetamide, α -(methoxyimino)-N-methyl-2-[2-[1-(3-methylphenyl)-5-(trifluoromethyl)-1H-pyrazol-4-yl]ethenyl]-, (E,E)-;
- RN 175424-70-1, Benzeneacetamide, 2-[2-[1-(3-chlorophenyl)-1H-pyrazol-4-yl]ethenyl]- α -(methoxyimino)-N-methyl-, (E,E)-;

useful as pesticides.

Claims 1-7, 9, 11 and 14- 16 are rejected under 35 U.S.C. 102(b) as being anticipated by Oberdorf, et al., US 5707936, issued 19980113 describing

- RN 174182-90-2, Benzeneacetic acid, 2-[[[1-(4-chlorophenyl)-1H-pyrazol-3-yl]oxy]methyl]- α -ethylidene-, methyl ester;
- RN 174182-94-6, Benzeneacetic acid, α -ethylidene-2-[[1-(1-phenyl-1H-pyrazol-3-yl)oxy]methyl]-, methyl ester;

Art Unit: 1624

- RN 174182-95-7, Benzeneacetic acid, α -ethylidene-2-[[[1-(4-methylphenyl)-1H-pyrazol-3-yl]oxy]methyl]-, methyl ester;
- RN 174182-96-8, Benzeneacetic acid, 2-[[[1-(3-chlorophenyl)-1H-pyrazol-3-yl]oxy]methyl]- α -ethylidene-, methyl ester;
- RN 174182-97-9, Benzeneacetic acid, α -ethylidene-2-[[[1-(4-fluorophenyl)-1H-pyrazol-3-yl]oxy]methyl]-, methyl ester;
- RN 174182-98-0, Benzeneacetic acid, 2-[[[1-(2,4-dichlorophenyl)-1H-pyrazol-3-yl]oxy]methyl]- α -ethylidene-, methyl ester;
- RN 174182-99-1, Benzeneacetic acid, 2-[[[1-(2,4-dimethylphenyl)-1H-pyrazol-3-yl]oxy]methyl]- α -ethylidene-, methyl ester;
- RN 174183-00-7, Benzeneacetic acid, 2-[[[1-(4-chloro-2-methylphenyl)-1H-pyrazol-3-yl]oxy]methyl]- α -ethylidene-, methyl ester;
- RN 174183-01-8, Benzeneacetic acid, 2-[[[1-(2-chlorophenyl)-1H-pyrazol-3-yl]oxy]methyl]- α -ethylidene-, methyl ester;
- RN 174183-02-9, Benzeneacetic acid, 2-[[[1-(3,5-dichlorophenyl)-1H-pyrazol-3-yl]oxy]methyl]- α -ethylidene-, methyl ester;
- RN 174183-03-0, Benzeneacetic acid, 2-[[[1-(2,6-dichlorophenyl)-1H-pyrazol-3-yl]oxy]methyl]- α -ethylidene-, methyl ester;
- RN 174183-04-1, Benzeneacetic acid, α -ethylidene-2-[[[1-(2-methylphenyl)-1H-pyrazol-3-yl]oxy]methyl]-, methyl ester;

Art Unit: 1624

- RN 174183-05-2, Benzeneacetic acid, α -ethylidene-2-[[[1-(3-methylphenyl)-1H-pyrazol-3-yl]oxy]methyl]-, methyl ester;
- RN 174183-06-3, Benzeneacetic acid, α -ethylidene-2-[[[1-(4-methoxyphenyl)-1H-pyrazol-3-yl]oxy]methyl]-, methyl ester;
- RN 174183-07-4, Benzeneacetic acid, 2-[[[1-(2,5-dichlorophenyl)-1H-pyrazol-3-yl]oxy]methyl]- α -ethylidene-, methyl ester;
- RN 174183-08-5, Benzeneacetic acid, 2-[[[1-(3,4-dichlorophenyl)-1H-pyrazol-3-yl]oxy]methyl]- α -ethylidene-, methyl ester;
- RN 174183-09-6, Benzeneacetic acid, α -ethylidene-2-[[[1-[3-(trifluoromethyl)phenyl]-1H-pyrazol-3-yl]oxy]methyl]-, methyl ester;
- RN 174183-10-9, Benzeneacetic acid, α -ethylidene-2-[[[1-[5-(trifluoromethyl)-2-pyridinyl]-1H-pyrazol-3-yl]oxy]methyl]-, methyl ester;
- RN 174183-11-0, Benzeneacetic acid, 2-[[[4-chloro-1-(4-methylphenyl)-1H-pyrazol-3-yl]oxy]methyl]- α -ethylidene-, methyl ester;
- RN 174183-12-1, Benzeneacetic acid, 2-[[[4-chloro-1-(4-chlorophenyl)-1H-pyrazol-3-yl]oxy]methyl]- α -ethylidene-, methyl ester;
- RN 174183-13-2, Benzeneacetic acid, α -ethylidene-2-[[[1-(3-methoxyphenyl)-1H-pyrazol-3-yl]oxy]methyl]-, methyl ester;
- RN 174183-14-3, Benzeneacetic acid, 2-[[[1-(2,2-difluoro-2,3-dihydro-1H-inden-5-yl)-1H-pyrazol-3-yl]oxy]methyl]- α -ethylidene-, methyl ester;

Art Unit: 1624

- RN 174183-15-4, 1H-Pyrazole-4-carboxylic acid, 1-(4-chlorophenyl)-3-[[2-[1-(methoxycarbonyl)-1-propenyl]phenyl]methoxy]-, methyl ester;
- RN 174183-16-5, 1H-Pyrazole-4-carboxylic acid, 1-(2,4-dichlorophenyl)-3-[[2-[1-(methoxycarbonyl)-1-propenyl]phenyl]methoxy]-, methyl ester;
- RN 174183-17-6, Benzeneacetic acid, α -ethylidene-2-[[[1-[4-(trifluoromethyl)phenyl]-1H-pyrazol-3-yl]oxy]methyl]-, methyl ester;
- RN 174183-18-7, Benzeneacetic acid, α -ethylidene-2-[[[1-(2-pyridinyl)-1H-pyrazol-3-yl]oxy]methyl]-, methyl ester;
- RN 174183-19-8, Benzeneacetic acid, α -ethylidene-2-[[[5-methyl-1-phenyl-1H-pyrazol-3-yl]oxy]methyl]-, methyl ester;
- RN 174183-20-1, Benzeneacetic acid, 2-[[[1-(2,4-dichlorophenyl)-5-(trifluoromethyl)-1H-pyrazol-3-yl]oxy]methyl]- α -ethylidene-, methyl ester;
- RN 174183-21-2, Benzeneacetic acid, 2-[[[1-(2,4-dichlorophenyl)-4-nitro-1H-pyrazol-3-yl]oxy]methyl]- α -ethylidene-, methyl ester;
- RN 174183-22-3, Benzeneacetic acid, 2-[[[4-chloro-1-(2,4-dichlorophenyl)-1H-pyrazol-3-yl]oxy]methyl]- α -ethylidene-, methyl ester;
- RN 174183-23-4, 1H-Pyrazole-4-carboxylic acid, 3-[[2-[1-(methoxycarbonyl)-1-propenyl]phenyl]methoxy]-1-phenyl-, methyl ester;
- RN 174183-24-5, Benzeneacetic acid, 2-[[[4-chloro-1-[5-(trifluoromethyl)-2-pyridinyl]-1H-pyrazol-3-yl]oxy]methyl]- α -ethylidene-, methyl ester;
- RN 174183-25-6, Benzeneacetic acid, 2-chloro-6-[[[1-(2,4-dichlorophenyl)-1H-pyrazol-3-yl]oxy]methyl]- α -ethylidene-, methyl ester;

Art Unit: 1624

- RN 174183-26-7, Benzeneacetic acid, 2-chloro-6-[[[1-(3,5-dichlorophenyl)-1H-pyrazol-3-yl]oxy]methyl]- α -ethylidene-, methyl ester;
- RN 174183-27-8, Benzeneacetic acid, 2-chloro- α -ethylidene-6-[[[1-(4-methoxyphenyl)-1H-pyrazol-3-yl]oxy]methyl]-, methyl ester;
- RN 174183-28-9, Benzeneacetic acid, 2-chloro- α -ethylidene-6-[[[1-[5-(trifluoromethyl)-2-pyridinyl]-1H-pyrazol-3-yl]oxy]methyl]-, methyl ester;
- RN 174183-34-7, Benzeneacetic acid, 2-[[[1-(5-chloro-2-pyridinyl)-1H-pyrazol-3-yl]oxy]methyl]- α -ethylidene-, methyl ester;
- RN 174183-35-8, Benzeneacetic acid, 2-[[[1-(6-chloro-3-pyridazinyl)-1H-pyrazol-3-yl]oxy]methyl]- α -ethylidene-, methyl ester;
- RN 174183-36-9, Benzeneacetic acid, α -ethylidene-2-[[[1-pyrazinyl-1H-pyrazol-3-yl]oxy]methyl]-, methyl ester;
- RN 174183-37-0, Benzeneacetic acid, 2-[[[4-chloro-1-phenyl-1H-pyrazol-3-yl]oxy]methyl]- α -ethylidene-, methyl ester;
- RN 174183-38-1, Benzeneacetic acid, 2-[[[4-chloro-1-pyrazinyl-1H-pyrazol-3-yl]oxy]methyl]- α -ethylidene-, methyl ester;
- RN 174183-39-2, Benzeneacetic acid, 2-[[[4-bromo-1-(4-chlorophenyl)-1H-pyrazol-3-yl]oxy]methyl]- α -ethylidene-, methyl ester;
- RN 174183-40-5, Benzeneacetic acid, α -ethylidene-2-[[[4-nitro-1-[5-(trifluoromethyl)-2-pyridinyl]-1H-pyrazol-3-yl]oxy]methyl]-, methyl ester;

Art Unit: 1624

- RN 174182-93-5, Benzeneacetic acid, α -ethylidene-2-[[[1-(6-fluoro-2-pyridinyl)-1H-pyrazol-3-yl]oxy]methyl]-, methyl ester;
- RN 174183-42-7, Benzeneacetic acid, 2-[[[1-(2-chloro-4-fluorophenyl)-1H-pyrazol-3-yl]oxy]methyl]- α -ethylidene-, methyl ester; and
- RN 174183-43-8, Benzeneacetic acid, α -ethylidene-2-[[[1-(4-fluoro-2-methylphenyl)-1H-pyrazol-3-yl]oxy]methyl]-, methyl ester;

useful as fungicides and pesticides.

Claims 1-7, 9, 11 and 14- 16 are rejected under 35 U.S.C. 102(b) as being anticipated by Hwang, et al., US 5776965, issued 19980707, describing

- RN 172834-81-0, Benzeneacetic acid, α -(methoxymethylene)-2-[[[1-phenyl-3-(trifluoromethyl)-1H-pyrazol-4-yl]oxy]methyl]-, methyl ester, (E)-;
- RN 172834-82-1, Benzeneacetic acid, α -(methoxyimino)-2-[[[1-phenyl-3-(trifluoromethyl)-1H-pyrazol-4-yl]oxy]methyl]-, methyl ester, (Z)-;
- RN 172834-83-2, Benzeneacetic acid, α -(methoxyimino)-2-[[[1-phenyl-3-(trifluoromethyl)-1H-pyrazol-4-yl]oxy]methyl]-, methyl ester, (E)-;
- RN 172834-84-3, Benzeneacetic acid, α -(methoxymethylene)-2-[[[3-methyl-1-phenyl-1H-pyrazol-4-yl]oxy]methyl]-, methyl ester, (E)-;
- RN 172834-85-4, Benzeneacetic acid, α -[(methylthio)methylene]-2-[[[1-phenyl-3-(trifluoromethyl)-1H-pyrazol-4-yl]oxy]methyl]-, methyl ester, (E)-;
- RN 172834-86-5, Benzeneacetic acid, α -oxo-2-[[[1-phenyl-3-(trifluoromethyl)-1H-pyrazol-4-yl]oxy]methyl]-, methyl ester;

Art Unit: 1624

useful as fungicides.

Claims 1-7, 9, 11, 14 and 15 are rejected under 35 U.S.C. 102(b) as being anticipated by Huang, et al., US 5236938, issued 19930817, describing RN 162368-35-6, Benzoic acid, 4-[[[3-cyano-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-4-[(trifluoromethyl)thio]-1H-pyrazol-5-yl]imino]methyl]-, methyl ester; and RN 162368-36-7, Benzoic acid, 4-[[[3-cyano-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-4-[(trifluoromethyl)thio]-1H-pyrazol-5-yl]imino]methyl]-2-methoxy-, methyl ester; useful as pesticides.

Claims 1-7, 9, 11 and 14-16 are rejected under 35 U.S.C. 102(b) as being anticipated by Kirstgen, et al., US 6031110, issued 20000229, describing

- RN 158668-47-4, Benzeneacetamide, α -(methoxyimino)-N-methyl-2-[[[1-phenyl-1H-pyrazol-4-yl]oxy]methyl]-;
- RN 158668-48-5, Benzeneacetamide, 2-[[[1-(4-fluorophenyl)-1H-pyrazol-4-yl]oxy]methyl]- α -(methoxyimino)-N-methyl-;
- RN 158668-49-6, Benzeneacetamide, α -(methoxyimino)-N-methyl-2-[[[1-[4-(trifluoromethyl)phenyl]-1H-pyrazol-4-yl]oxy]methyl]-;
- RN 158668-50-9, Benzeneacetamide, 2-[[[1-(4-cyanophenyl)-1H-pyrazol-4-yl]oxy]methyl]- α -(methoxyimino)-N-methyl-;
- RN 158668-51-0, Benzeneacetamide, α -(methoxyimino)-N-methyl-2-[[[1-(4-methylphenyl)-1H-pyrazol-4-yl]oxy]methyl]-;

Art Unit: 1624

- RN 158668-52-1, Benzeneacetamide, 2-[[[1-(4-chlorophenyl)-1H-pyrazol-4-yl]oxy]methyl]- α -(methoxyimino)-N-methyl-;
- RN 158668-53-2, Benzeneacetamide, 2-[[[1-(2,4-dichlorophenyl)-1H-pyrazol-4-yl]oxy]methyl]- α -(methoxyimino)-N-methyl-;
- RN 158668-54-3, Benzeneacetamide, 2-[[[1-(4-chloro-2-methylphenyl)-1H-pyrazol-4-yl]oxy]methyl]- α -(methoxyimino)-N-methyl-, (E)-;

useful as fungicides and insecticides.

Claims 1-7, 9, 11 and 14 are rejected under 35 U.S.C. 102(b) as being anticipated by Hwang, et al., WO 9400436, published 19940106, describing

- RN 154315-23-8, Benzeneacetic acid, α -(methoxymethylene)-2-[[[1-phenyl-3-(trifluoromethyl)-1H-pyrazol-5-yl]oxy]methyl]-, methyl ester, (Z)-;
- RN 154315-24-9, Benzeneacetic acid, α -(methoxymethylene)-2-[[[1-phenyl-3-(trifluoromethyl)-1H-pyrazol-5-yl]oxy]methyl]-, methyl ester, (E)-;
- RN 154315-25-0, Benzeneacetic acid, α -(methoxyimino)-2-[[[1-(2-pyridinyl)-3-(trifluoromethyl)-1H-pyrazol-5-yl]oxy]methyl]-, methyl ester;
- RN 154315-40-9, Benzeneacetic acid, α -oxo-2-[[[1-phenyl-3-(trifluoromethyl)-1H-pyrazol-5-yl]oxy]methyl]-, methyl ester; and
- RN 154315-41-0, Benzeneacetic acid, α -oxo-2-[[[1-(2-pyridinyl)-3-(trifluoromethyl)-1H-pyrazol-5-yl]oxy]methyl]-, methyl ester;

Useful as fungicides.

Art Unit: 1624

Claims 1-7, 9, 11, 12, 14 and 15 are rejected under 35 U.S.C. 102(b) as being anticipated by Kasahara, et al., WO 9307138, published 19930415, describing

- RN 150400-56-9, Benzoic acid, 4-[[5-methoxy-1-(6-methyl-2-pyridinyl)-1H-pyrazol-3-yl]methyl]-;
- RN 150400-57-0, Benzoic acid, 4-[[5-methoxy-1-(6-methyl-2-pyridinyl)-1H-pyrazol-3-yl]methyl]-, methyl ester;
- RN 150400-58-1, Benzamide, 4-[[5-methoxy-1-(6-methyl-2-pyridinyl)-1H-pyrazol-3-yl]methyl]-;
- RN 150400-61-6, Carbamic acid, [4-[[5-methoxy-1-(6-methyl-2-pyridinyl)-1H-pyrazol-3-yl]methyl]phenyl]-, ethyl ester; and
- RN 150400-78-5, Benzoic acid, 4-[[5-methoxy-4-methyl-1-(6-methyl-2-pyridinyl)-1H-pyrazol-3-yl]methyl]-, methyl ester;

useful as fungicides.

Claims 1-7, 11, 12 and 14-16 are rejected under 35 U.S.C. 102(b) as being anticipated by Kirstgen, et al., US 5403838, issued 19950404, describing

- RN 148001-21-2, Benzeneacetic acid, 2-[2-[1-(4-chlorophenyl)-3-methyl-1H-pyrazol-4-yl]ethenyl]- α -(methoxymethylene)-, methyl ester, (E,?)-;
- RN 148001-22-3, Benzeneacetic acid, 2-[2-[1-(4-chlorophenyl)-3,5-dimethyl-1H-pyrazol-4-yl]ethenyl]- α -(methoxymethylene)-, methyl ester, (E,?)-;
- RN 148001-23-4, Benzeneacetic acid, α -(methoxymethylene)-2-[2-(5-methyl-1-phenyl-1H-pyrazol-4-yl)ethenyl]-, methyl ester, (E,?)-;

Art Unit: 1624

- RN 148001-24-5, Benzeneacetic acid, 2-[2-[1-(4-chlorophenyl)-5-methyl-1H-pyrazol-4-yl]ethenyl]- α -(methoxymethylene)-, methyl ester, (E,?)-;

Useful as pesticides.

Claims 1-7, 11, 12 and 14-16 are rejected under 35 U.S.C. 102(b) as being anticipated by Sauter, et al., US 5538940, issued 19960723, describing

- RN 147500-08-1, 2-Propenoic acid, 3-[2-[2-[1-(3-chlorophenyl)-1H-pyrazol-4-yl]ethenyl]phenyl]-3-methoxy-, methyl ester, (E,E)-;
- RN 147500-09-2, 2-Propenoic acid, 3-[2-[2-[1-(3-chlorophenyl)-1H-pyrazol-4-yl]ethenyl]phenyl]-3-methoxy-, methyl ester, (E,Z)-;
- RN 147500-10-5, 2-Propenoic acid, 3-methoxy-3-[2-[2-[1-(4-methoxyphenyl)-1H-pyrazol-4-yl]ethenyl]phenyl]-, methyl ester, (E,E)-;
- RN 147500-11-6, 2-Propenoic acid, 3-methoxy-3-[2-[2-[1-(4-methoxyphenyl)-1H-pyrazol-4-yl]ethenyl]phenyl]-, methyl ester, (E,Z)-;
- RN 147500-12-7, 2-Propenoic acid, 3-[2-[2-[1-(4-chlorophenyl)-1H-pyrazol-4-yl]ethenyl]phenyl]-3-methoxy-, methyl ester, (E,E)-; and
- RN 147500-13-8, 2-Propenoic acid, 3-[2-[2-[1-(4-chlorophenyl)-1H-pyrazol-4-yl]ethenyl]phenyl]-3-methoxy-, methyl ester, (E,Z)-;

useful as inhibitors of mitochondrial respiration.

Claims 1-7, 9, 11 and 14-16 are rejected under 35 U.S.C. 102(b) as being anticipated by Grammenos, et al., US 5298527, issued 19940329, describing

Art Unit: 1624

- RN 145910-25-4, Benzeneacetic acid, 2-[[[1-(4-chlorophenyl)-1H-pyrazol-4-yl]oxy]methyl]- α -ethylidene-, methyl ester, (E)-;
- RN 145910-64-1, Benzeneacetic acid, 2-[[[1-(2,4-dichlorophenyl)-1H-pyrazol-4-yl]oxy]methyl]- α -ethylidene-, methyl ester, (E)-;
- RN 145911-10-0, Benzeneacetic acid, 2-[2-[1-(4-chlorophenyl)-1H-pyrazol-4-yl]ethenyl]- α -ethylidene-, methyl ester, (E,E)-;
- RN 145911-49-5, Benzeneacetic acid, α -ethylidene-2-[[1-(phenyl)-1H-pyrazol-4-yl]oxy]methyl]-, methyl ester, (E)-;
- RN 145911-50-8, Benzeneacetic acid, α -ethylidene-2-[[[1-(4-methylphenyl)-1H-pyrazol-4-yl]oxy]methyl]-, methyl ester, (E)-;
- RN 145911-51-9, Benzeneacetic acid, α -ethylidene-2-[[[1-(4-fluorophenyl)-1H-pyrazol-4-yl]oxy]methyl]-, methyl ester, (E)-; and
- RN 145911-74-6, Benzeneacetic acid, 2-[[[1-(4-cyanophenyl)-1H-pyrazol-4-yl]oxy]methyl]- α -ethylidene-, methyl ester, (E)-;

useful as fungicides.

Claims 1-7, 10, 11, 12 and 14-16 are rejected under 35 U.S.C. 102(b) as being anticipated by Sauter, et al., US 5334607, issued 19940802, describing RN 145849-23-6, Benzeneacetic acid, α -(methoxymethylene)-2-[2-(1-phenyl-1H-pyrazol-4-yl)ethenyl]-, methyl ester, (E,?)-, useful as antimycotics.

Claims 1-8 and 11-16 are rejected under 35 U.S.C. 102(b) as being anticipated

Art Unit: 1624

by Oda, et al., US 5055477, issued 19911008, describing RN 136193-00-5, 1H-Pyrazole-5-acetic acid, α -(methoxymethylene)-1,3-dimethyl-4-[(2-phenyl-4-thiazolyl)methoxy]-, methyl ester, (E)-; and RN 136193-01-6, 1H-Pyrazole-5-acetic acid, α -(methoxymethylene)-1,3-dimethyl-4-[(2-phenyl-4-thiazolyl)methoxy]-, methyl ester, (Z)-; useful as fungicides.

Claims 1-9 and 12-14 are rejected under 35 U.S.C. 102(b) over Go, et al., JP 61197559, published 19860901, describing RN 105675-70-5, Urea, N'-[3-chloro-4-[(5-methyl-3-phenyl-1H-pyrazol-1-yl)methoxy]phenyl]- N,N-dimethyl-; useful as herbicides.

Claims 1-8, 11-15 and 19-30 are rejected under 35 U.S.C. 102(b) as being anticipated by Elbe, et al., DE 3300795, published 19840712, describing RN 92782-09-7, Benzoic acid, 4-[2-[4-(1H-imidazol-1-yl)-1H-pyrazol-3-yl]-2-methylpropoxy]-, and RN 92782-16-6, Benzoic acid, 4-[2-[4-(1H-imidazol-1-yl)-1H-pyrazol-3-yl]-2-methylpropoxy]-, methyl ester, with antithromboembolic action. The intended use of the pharmaceutical compositions is given no patentable weight.

Claims 1-7, 10, 11, 14 and 15 are rejected under 35 U.S.C. 102(b) over Lange, et al., Zeitschrift fuer Chemie (1977), 17(3), 94-5, describing RN 63451-62-7, Benzoic acid, 3-[[[3-methyl-4-nitro-1-(4-nitrophenyl)-1H-pyrazol-5-yl]amino]methyl]-.

Claims 1-9, 11, 12 and 14 are rejected under 35 U.S.C. 102(b) over Izumi, et al.,

Art Unit: 1624

Yakugaku Zasshi (~~1973~~), 93(10), 1349-55, describing RN 51862-40-9, Benzoic acid, 2-[[[(5-methoxy-1-phenyl-1H-pyrazol-3-yl)acetyl]amino]-, methyl ester.

Claims 1-9, 11, 12, 14 and 15 are rejected under 35 U.S.C. 102(b) as being anticipated by Felix, et al., Monatshefte fuer Chemie (~~1910~~), 31, 55-79, describing RN 861527-19-7, Anthranilic acid, N-(5-hydroxy-3-methyl-1-phenyl-4-pyrazolylmethylene)-, useful as an indigoid dye.

Claims 1-9, 11, 12, 14 and 15 are rejected under 35 U.S.C. 102(b) as being anticipated by Meanwell, US 4956376, issued Nov. 9, 1990. See Ex. 24-27. These compounds are useful as inhibitors of mammalian blood platelet aggregation.

Objected Claims

Claim 17 is objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims.

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Cecilia M. Jaisle, J.D. whose telephone number is 571-272-9931. The examiner can normally be reached on Monday through Friday; 8:30 am through 5:00 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, James O. Wilson can be reached on 571-272-0661. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

**/James O. Wilson/
Supervisory Patent Examiner
Art Unit 1624**

Cecilia M. Jaisle, J.D.
10/10/2007